Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Semnur Pharmaceuticals ( (SMNR) ) has shared an update.
On September 22, 2025, Semnur Pharmaceuticals, Inc. and Denali Capital Acquisition Corp. completed their business combination, with Semnur’s shares expected to trade under the ticker symbols ‘SMNR’ and ‘SMNRW’ on the OTC Markets. This merger positions Semnur to leverage public capital markets for growth, focusing on advancing non-opioid pain management therapies. The company aims to enhance its market presence by progressing its SP-102 clinical development and expanding payer adoption.
More about Semnur Pharmaceuticals
Semnur Pharmaceuticals, Inc. is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Its primary product candidate, SP-102 (SEMDEXA™), is a non-opioid gel formulation for epidural administration, targeting moderate to severe chronic radicular pain/sciatica. Semnur is headquartered in Palo Alto, California.
Average Trading Volume: 325
Technical Sentiment Signal: Buy
Current Market Cap: $10.52M
See more data about SMNR stock on TipRanks’ Stock Analysis page.